Abbott Laboratories
Search results
May 7, 2024 · AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. [2] The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered via injection.
NORTH CHICAGO, Ill. - AbbVie (NYSE:ABBV) has officially applied for approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to use its drug upadacitinib for treating adults with giant cell arteritis (GCA). This autoimmune disease affects medium and large ...
Feb 12, 2024 · AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio. ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative ...
Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.
Get the latest AbbVie Inc (ABBV) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
AbbVie formed a new kind of enterprise – a biopharmaceutical company – with the stability, global scale, resources and commercial capabilities of a pharmaceutical company and the focus and culture of a biotech. Since the beginning, our mission hasn't wavered.
Jul 3, 2024 · AbbVie lowered its 2024 adjusted profit forecast on Wednesday, citing $937 million in milestones, and research and development expenses related to acquisitions.
4 days ago · AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues...
